Journal
CLINICAL IMMUNOLOGY
Volume 146, Issue 1, Pages 15-25Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2012.10.008
Keywords
Mouse model; Autoimmune hepatitis; TNF-alpha; CCL20; TNF-alpha antagonist
Categories
Funding
- Special Coordination Funds for Promoting Science and Technology of the Japanese Government
- Astellas Pharma Inc. in the Formation of Innovation Center for the Fusion of Advanced Technologies Program
- Japan Society for the Promotion of Science (JSPS) [21229009, 23590973]
- Ministry of Health, Labour and Welfare, Japan
- Kato Memorial Trust for Nambyo Research
- Waksman Foundation of Japan
- Grants-in-Aid for Scientific Research [24659151, 23590973] Funding Source: KAKEN
Ask authors/readers for more resources
It is unclear what roles TNF-alpha has in the development of autoimmune hepatitis (AIH) and whether AIH is responsive to anti-TNF-alpha. We recently developed a mouse model of fatal AIH that develops in PD-1-deficient mice thymectomized three days after birth, finding that CCR6-CCL20 axis-dependent migration of dysregulated splenic T cells is crucial to induce AIH. In this study, we show the indispensable role of TNF-alpha in the development of AIH. Administering anti-TNF-alpha prevented the induction, but treatment by anti-TNF-alpha after the induction did not suppress progression. Administering anti-TNF-alpha did not prevent splenic T-cell activation, but did suppress hepatic CCL20 expression. In contrast, administering anti-CCL20 suppressed AIH but not elevated serum TNF-alpha levels. TNF-alpha stimulation enhanced CCL20 expression in hepatocytes. These findings suggest that TNF-alpha is essential in the induction of AIH through upregulation of hepatic CCL20 expression, which allows migration of dysregulated splenic T cells. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available